Are urine metabolomics able to differentiate between healthy controls (HC), RA, SLE, & SpA? Small study of prevalent pts showed SLE and RA metabolomics v diff from controls and SpA. Don't know if diff early or pre clinical disease #ACR19 @RheumNow abstr 2127 https://t.co/mBh5nxRcqk

5-year effectiveness of TNFi in patients with early axSpA shown, male gender, HLAB27 positive and presence of at least one objective sign of inflammation or structural damage are more frequently associated with effectiveness #2776 by Molto #ACR19 @RheumNow

What dose of MTX do you usually start with in a newly diagnosed rheumatoid arthritis patient? #ACR19 @RheumNow

@_connectedcare @RheumNow @ACRheum My pearls (so far) 1. Use vitamin A to reduce SEs w MTX 2. Try doxycycline for refractory calcinosis in scleroderma 3. Use MTX with pegloticase to reduce infusion reactions 4. Anti-IL17 has activity in nr-axSpA 5. Patients think opiates are more effective than SNRIs or TCAs in FM

@RheumNow #ACR19 #acrbest abs2470 ⬆️serum calprotectin in PsA pts associated w/presence of carotid plaque, ⬆️intima-media thickness & ⬆️CRP. potential novel bio marker of CV disease in PsA https://t.co/ech3Ll8Nka

As I leave #acr19, time to reflect. My goal is to uncover pearls that change what I do in my next few clinics. 3 this time. How many such pearls did you find? @RheumNow @ACRheum

@rheumnow #ACR19 abs2854 internationPsART cohort data: age of onset defines if PSO or PSA starts first (PSO precedes in younger pts), Pustular PSO associated w/shorter time interval PSO to arthritis while nail involvement, plaque PSO & PSO family Hx associated w/ longer interval https://t.co/KtPXhYdbky

Do you still look at synovial fluid under the microscope? @rheumnow #acr19

Baricitinib additional improvement in pain vs ADA despite accounting for effect on disease activity https://t.co/zAjS2dOayF @RheumNow

• https://assets.ctfassets.net/mpejy6umgthp/1GddGCUl6UX0JRJSqYBpVW/59031ed6ebb6b6…

Claims data showing switching from ETN or ADA to Tofa had higher drug survival vs cycling to another TNF. Does not provide reason for discontinuation though https://t.co/yTNHkKanJA @RheumNow #ACR19

• american college of rheumatology acr 2019 arhp 2019 annual scientific meeti 57…

Weight loss in IgG4-RD NOT because of overwhelming systemic inflammation but from pancreatic involvement. Need pancreatic enzyme replacement. #ACR19 @RheumNow

Abstr#2729: 303 pts randomized. More pts achieved ASAS40 at Wk 16: IXE Q2W (40%), IXE Q4W (35%) vs PBO (19%, p< 0.01) and at Wk 52: IXE Q2W (31%), IXE Q4W (30%) vs PBO (13%, p< 0.01). Blocking IL-17A is a potential treatment option for patients with nr-axSpA. #ACR19 @RheumNow

Fantastic view of how specific defects in the immune system lead to various clinical presentations and laboratory abnormalities. Dr. Mahta Mortezavi #ACR19 @RheumNow https://t.co/ht7VBhDdpR

Drs. Davila and Solow say “No good data to suggest that biologic DMARDs contribute to progression of MGUS so okay to treat as you normally would.” #ACR19 @RheumNow https://t.co/5r2W4q1t5c

While immunoglobulin replacement for patients with CVID prevents infections, it does not correct any of the autoimmune features....keeping rheumatologists busy! Dr. Mahta Mortezavi #ACR19 @RheumNow